P Y Kwo

Summary

Affiliation: Indiana University
Country: USA

Publications

  1. doi request reprint Boceprevir and treatment of chronic hepatitis C
    Paul Y Kwo
    Gastroenterology Hepatology Division, Indiana University School of Medicine, Indianapolis, 46202 5121, USA
    Clin Liver Dis 17:63-72. 2013
  2. doi request reprint Shortness of breath in the patient with chronic liver disease
    Paul Y Kwo
    Gastroenterology Hepatology Division, Indiana University School of Medicine, Indianapolis, 46202 5121, USA
    Clin Liver Dis 16:321-9. 2012
  3. doi request reprint Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin
    Paul Y Kwo
    Liver Transplantation Gastroenterology Hepatology Division, Indiana University School of Medicine, Indianapolis, IN 46202 5121, USA
    Liver Int 32:39-43. 2012
  4. pmc Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment
    Milton W Taylor
    Department of Biology, Indiana University, Bloomington, IN 47401, USA
    J Transl Med 6:66. 2008
  5. doi request reprint Boceprevir: a user's guide
    Paul Y Kwo
    Liver Transplantation, Gastroenterology Hepatology Division, Indiana University School of Medicine, Indianapolis, IN 46202 5121, USA
    Clin Liver Dis 15:537-53. 2011
  6. doi request reprint Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
    Paul Y Kwo
    Department of Medicine, Division of Gastroenterology Hepatology, Indiana University School of Medicine, Indianapolis, IN 46202 5121, USA
    Lancet 376:705-16. 2010
  7. ncbi request reprint Granulomatous liver disease
    Sidharth S Bhardwaj
    Division of Gastroenterology Hepatology, 975 West Walnut Street, IB 327, Indianapolis, IN 46202 5121, USA
    Curr Gastroenterol Rep 11:42-9. 2009
  8. ncbi request reprint Intravenous interferon during the anhepatic phase of liver retransplantation and prevention of recurrence of cholestatic hepatitis C virus
    Paul Y Kwo
    Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202 5121, USA
    Liver Transpl 13:1710-3. 2007
  9. ncbi request reprint Gender differences in alcohol metabolism: relationship to liver volume and effect of adjusting for body mass
    P Y Kwo
    Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Gastroenterology 115:1552-7. 1998
  10. ncbi request reprint Treatment of chronic hepatitis C in nonresponders to interferon monotherapy
    P Y Kwo
    Division of Gastroenterology Hepatology, Indiana University School of Medicine, 975 West Walnut Street, IB 424, Indianapolis, IN 46202 5121, USA
    Curr Gastroenterol Rep 2:11-7. 2000

Collaborators

Detail Information

Publications28

  1. doi request reprint Boceprevir and treatment of chronic hepatitis C
    Paul Y Kwo
    Gastroenterology Hepatology Division, Indiana University School of Medicine, Indianapolis, 46202 5121, USA
    Clin Liver Dis 17:63-72. 2013
    ..Further follow-up in these cohorts will be required...
  2. doi request reprint Shortness of breath in the patient with chronic liver disease
    Paul Y Kwo
    Gastroenterology Hepatology Division, Indiana University School of Medicine, Indianapolis, 46202 5121, USA
    Clin Liver Dis 16:321-9. 2012
    ..Shortness of breath in patients with cirrhosis often portends a poor prognosis, and these patients should be evaluated for orthotopic liver transplant because this therapy is most likely to provide long-lasting benefit...
  3. doi request reprint Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin
    Paul Y Kwo
    Liver Transplantation Gastroenterology Hepatology Division, Indiana University School of Medicine, Indianapolis, IN 46202 5121, USA
    Liver Int 32:39-43. 2012
    ..On-treatment viral response is also predictive of the SVR: approximately half of the patients are successfully treated with short duration and response-guided therapy...
  4. pmc Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment
    Milton W Taylor
    Department of Biology, Indiana University, Bloomington, IN 47401, USA
    J Transl Med 6:66. 2008
    ....
  5. doi request reprint Boceprevir: a user's guide
    Paul Y Kwo
    Liver Transplantation, Gastroenterology Hepatology Division, Indiana University School of Medicine, Indianapolis, IN 46202 5121, USA
    Clin Liver Dis 15:537-53. 2011
    ..This review discusses the mechanism of action of boceprevir, its effects on HCV, and its viral resistance...
  6. doi request reprint Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
    Paul Y Kwo
    Department of Medicine, Division of Gastroenterology Hepatology, Indiana University School of Medicine, Indianapolis, IN 46202 5121, USA
    Lancet 376:705-16. 2010
    ..We tested the efficacy of boceprevir, an NS3 hepatitis C virus oral protease inhibitor, when added to peginterferon alfa-2b and ribavirin...
  7. ncbi request reprint Granulomatous liver disease
    Sidharth S Bhardwaj
    Division of Gastroenterology Hepatology, 975 West Walnut Street, IB 327, Indianapolis, IN 46202 5121, USA
    Curr Gastroenterol Rep 11:42-9. 2009
    ..Therapy may be warranted, either directly for the granulomatous inflammation of the liver or for a systemic process. For some patients, observation may be the most appropriate form of management...
  8. ncbi request reprint Intravenous interferon during the anhepatic phase of liver retransplantation and prevention of recurrence of cholestatic hepatitis C virus
    Paul Y Kwo
    Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202 5121, USA
    Liver Transpl 13:1710-3. 2007
    ..The role of anhepatic administration of interferon deserves further examination, and this combination may provide a solution in a subset of patients with an otherwise poor prognosis...
  9. ncbi request reprint Gender differences in alcohol metabolism: relationship to liver volume and effect of adjusting for body mass
    P Y Kwo
    Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Gastroenterology 115:1552-7. 1998
    ..Some studies have demonstrated faster rates of alcohol elimination in women. This study examined whether gender differences in alcohol metabolism are related to differences in liver volume and/or differences in lean body mass...
  10. ncbi request reprint Treatment of chronic hepatitis C in nonresponders to interferon monotherapy
    P Y Kwo
    Division of Gastroenterology Hepatology, Indiana University School of Medicine, 975 West Walnut Street, IB 424, Indianapolis, IN 46202 5121, USA
    Curr Gastroenterol Rep 2:11-7. 2000
    ..Preliminary results from two trials in the United States demonstrate similar treatment efficacy. There is now evidence that maintenance interferon therapy may also be beneficial in interferon monotherapy nonresponders...
  11. doi request reprint Boceprevir, an NS3 protease inhibitor of HCV
    Kenneth Berman
    Department of Medicine, Division of Gastroenterology Hepatology, Indiana University School of Medicine, Indianapolis, IN 46202 5121, USA
    Clin Liver Dis 13:429-39. 2009
    ..This review focuses on boceprevir, a protease inhibitor, and discusses its mechanism of action, effects on HCV, and viral resistance...
  12. ncbi request reprint Management of hepatitis C infection after liver transplantation
    Mazen Alsatie
    Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Drugs 67:871-85. 2007
    ..Determination of optimal doses of both pegylated interferon and ribavirin, and guidance on when to stop treatment, as well as improving tolerability are important steps in achieving higher response rates and minimising drug toxicity...
  13. ncbi request reprint Simultaneous liver and pancreas transplantation in patients with cystic fibrosis
    J A Fridell
    Department of Surgery, Indiana University, 550 N University Boulevard 4258, Indianapolis, IN 46202, USA
    Transplant Proc 37:3567-9. 2005
    ..Liver transplantation is the treatment of choice for cirrhosis in this setting, but the addition of an isolated simultaneous pancreas transplant in patients with CFRD has not been reported...
  14. pmc Use of extended criteria livers decreases wait time for liver transplantation without adversely impacting posttransplant survival
    A Joseph Tector
    Department of Surgery, Transplantation Section, Gastroenterology Division, Indiana University School of Medicine, Indianapolis, IN 46202 5250, USA
    Ann Surg 244:439-50. 2006
    ..This study compares the graft/patient survival from standard (SD) and ECD for our transplant population between 2001 and 2005...
  15. ncbi request reprint Percutaneous stent placement as treatment of renal vein obstruction due to inferior vena caval thrombosis
    Michael S Stecker
    Department of Radiology, Vascular and Interventional Radiology Section, Indiana University School of Medicine, Indianapolis, IN 46202 5253, USA
    Cardiovasc Intervent Radiol 29:147-50. 2006
    ..This was treated by percutaneous placement of metallic stents from the renal veins to the right atrium. At 16 months clinical follow-up, the patient continues to do well...
  16. doi request reprint No difference in clinical transplant outcomes for local and imported liver allografts
    Richard S Mangus
    Clarian Transplant Institute, Indiana University School of Medicine, Indianapolis, IN 46202 5250, USA
    Liver Transpl 15:640-7. 2009
    ..In conclusion, liver allografts rejected for use by a large number of transplant centers can still be successfully used without early graft function or long-term survival being affected...
  17. pmc The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites
    V L Misra
    Indiana University School of Medicine, Indianapolis, USA
    Aliment Pharmacol Ther 32:1044-50. 2010
    ..Diminished glomerular filtration rate (GFR) is thought to mediate resistance to loop diuretics. Midodrine, a commonly used alpha-1 agonist, has been shown to improve GFR in non-azotemic patients with cirrhosis...
  18. doi request reprint Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations
    I M Jacobson
    Division of Gastroenterology and Hepatology, Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY 10021, USA
    J Viral Hepat 19:236-43. 2012
    ..Adoption of these terms would improve communication among investigators, enhance comparability among clinical trials, facilitate development of therapeutic guidelines and provide a standardized terminology for use in clinical practice...
  19. ncbi request reprint Effect of food and food composition on alcohol elimination rates in healthy men and women
    V A Ramchandani
    Department of Medicine, Indiana University School of Medicine, Indianapolis 46202-5121, USA
    J Clin Pharmacol 41:1345-50. 2001
    ..Probable mechanisms for the increased alcohol elimination includefood-induced increases in hepatic blood flow and in the activity of alcohol-metabolizing enzymes...
  20. ncbi request reprint A multivariable model of clinical variables predicts advanced fibrosis in chronic hepatitis C
    Mazen Alsatie
    Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    J Clin Gastroenterol 41:416-21. 2007
    ..Recent evidence suggests that obesity may contribute to hepatic fibrosis in hepatitis C virus infection...
  21. ncbi request reprint Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection
    Hong Shen
    Department of Medicine, Indiana University School of Medicine, Indianapolis, 46202, USA
    Clin Gastroenterol Hepatol 2:330-6. 2004
    ..In vitro data suggest that lamivudine and famciclovir might synergistically inhibit hepadnaviral replication. We reviewed our experience with lamivudine and famciclovir in 24 patients with chronic hepatitis B infection...
  22. doi request reprint Hepatobiliary abnormalities and disease in cystic fibrosis: epidemiology and outcomes through adulthood
    Sidharth Bhardwaj
    Division of Gastroenterology Hepatology, Indiana University Medical Center, Indianapolis, Indiana, USA
    J Clin Gastroenterol 43:858-64. 2009
    ..Our aim was to determine the prevalence of, and risk factors for, CF-related hepatobiliary abnormalities and determine factors that predict the development of CF-related hepatobiliary disease...
  23. ncbi request reprint Hepatobiliary disease in sarcoidosis
    Charles J Kahi
    Department of Medicine, Division of Gastroenterology and Hepatology, Indiana University Medical Center, Indianapolis, Indiana, USA
    Sarcoidosis Vasc Diffuse Lung Dis 23:117-23. 2006
    ..Sarcoidosis is a multisystem granulomatous disease of unknown etiology. Little is known about the prevalence, pattern, and risk factors for hepatobiliary disease in patients with sarcoidosis...
  24. ncbi request reprint Acute graft-versus-host disease of the lung after liver transplantation
    Kenneth S Knox
    Department of Medicine, Pulmonary Division, Indiana University School of Medicine, Indianapolis, IN, USA
    Liver Transpl 8:968-71. 2002
    ..High-dose corticosteroids were given with a return to baseline pulmonary function. The current case should alert clinicians to investigate pulmonary GVHD as a potential cause of postoperative dyspnea in liver transplant recipients...
  25. ncbi request reprint Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis
    William R Kessler
    Department of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, 46202, USA
    Clin Gastroenterol Hepatol 2:625-31. 2004
    ..The aim of this study was to compare clinical, biochemical, and histological features in patients with autoimmune hepatitis presenting with either acute or chronic hepatitis...
  26. ncbi request reprint Epidemiology of acute liver failure
    Mouen Khashab
    Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, 675 West Walnut, IB 327, Indianapolis, IN 46202, USA
    Curr Gastroenterol Rep 9:66-73. 2007
    ..Liver support systems show potential for the treatment of ALF, but their role needs validation in large multicenter randomized trials...
  27. ncbi request reprint Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1
    Ira M Jacobson
    Weill Medical College of Cornell University, Center for the Study of Hepatitis C, New York Presbyterian Hospital, New York, NY 10021, USA
    Hepatology 46:982-90. 2007
    ..SVR rates were higher (21% versus 10%; P = 0.0006) and relapse rates were lower (22% versus 30%) in the weight-based-dose group than in the flat-dose group. Safety and rates of drug discontinuation were similar between the 2 groups...
  28. ncbi request reprint Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial
    Ira M Jacobson
    Weill Medical College of Cornell University, Center for the Study of Hepatitis C, New York Presbyterian Hospital, New York, NY 10021, USA
    Hepatology 46:971-81. 2007
    ..8% and 59.5%, respectively) regardless of treatment duration. Besides greater hemoglobin reductions with weight-based RBV, safety profiles were similar across RBV dosing groups, including the 1400-mg/day group...